Revisiting the efficacy of bismuth subsalicylate for the prevention of traveller’s diarrhoea
What can be concluded from a clinical trial that spanned 5 years yet failed to achieve target enrollment, generated flat results that contradict the existing body of knowledge and has a primary efficacy endpoint confounded by a treatment-by-COVID interaction? Could it be a false negative finding?
Authors
- José M. Brum (ORCID: https://orcid.org/0000-0002-9216-6598)
- Roger Gibb (ORCID: https://orcid.org/0000-0001-5282-4616)
- Adam Pitz
- Benjamin T. Circello
- Kyle J. Sloan
- Rowan A. Grayling
Institutions
- Procter & Gamble (United States) (US)
Publication Details
- Journal
- Journal of Travel Medicine
- Published
- 2025-07-26
- DOI
- https://doi.org/10.1093/jtm/taaf076
- Citations
- 1
- Primary Topic
- Travel-related health issues
- Type
- article
- Field-Weighted Citation Impact
- 1.88
Funders
- Procter and Gamble
- Centers for Disease Control and Prevention